Your cart is empty.
Zurich, Switzerland, April 22, 2005 – Tecan Group Ltd. held its 19th Ordinary General Shareholders’ Meeting on April 21, 2005 in Zurich, where its shareholders approved the distribution of an unchanged dividend totalling CHF 0.45 per registered share. The shareholders also approved the six proposals on the agenda.
The shareholders adopted the annual report, the annual financial statements, and the consolidated financial statements, and granted discharge to the Board of Directors. They also approved the Board of Director's proposed appropriation of earnings. KPMG Fides Peat, Zurich, was confirmed as the auditor for the company and the group for fiscal year 2005.
The share buyback program has now been concluded. The Board of Directors repurchased and cancelled 453,000 registered shares in a second round of share buybacks. Share capital was thus reduced by 3.7% to CHF 11,887,606. There are no more share buybacks scheduled for 2005.
Tecan (www.tecan.com) is a leading player in the Life Sciences supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments, and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in
52 countries. In 2004, Tecan achieved sales of CHF 286.0 million (USD 230.6 million; EUR 185.7 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN / Reuters: TECZn.S / Valor : 1210019).
Tecan Group Ltd.
Corp. Communications & Investor Relations
Phone: +41 (0)44 922 84 30
Fax: +41 (0)44 922 88 89